Miguel Coego Ríos
CHIEF FINANCIAL OFFICER, IT AND LEGAL
Madrid
Summary
Dynamic and results-driven leader with extensive financial expertise and commercial acumen. Experience in leadership roles as CFO and General Manager. Demonstrated ability to drive financial turnarounds, execute complex capital-raising initiatives, lead strategic transformations and excel at Investor Relations as CFO of a NASDAQ-listed, PE-backed company. Proven success in securing multimillion-dollar investments and leading diverse teams across finance, IT, and legal functions. Adept at driving impactful M&A initiatives and managing all stages of the process, ensuring seamless operational alignment and value creation. Deep experience in pharmaceuticals, biotech, and rare diseases, delivering measurable results in high-growth, highly regulated environments.
Overview
23
23
years of professional experience
1
1
year of post-secondary education
3
3
Languages
Work History
CHIEF FINANCIAL OFFICER, IT AND LEGAL
CENTOGENE NV
Rostock
02.2022 - 12.2024
- Company Overview: PE Backed NASDAQ Listed Exome and Genome Diagnostics and Pharma services provider expert in Rare Diseases
- Complete turnaround of Profit and Loss performance from -90% EBITDA margin in '21 to -35% in '23, expected breakeven in Q4 '24 and cash generation in '25 (non-public information - NPI) (G&A -56%, R&D -48% in '24-'21)
- Positive closing of Charme Capital Partners acquisition of Centogene with more than €80m committed
- (NPI)
- Improvement of all accounting processes and controls addressing several Material Weaknesses identified on '21 audit process
- Obtention of financing investment in '23 by Saudi Public Audit Fund of $30m + $50m future milestones
- €25m non-recourse Account Receivable deal at face value (NPI)
- Setup of strong Financial Planning and Analysis cycle with regular Forecasts, deep business analysis and insights that did not exist in ‘21
- IT Management - Led the successful implementation of new ERP system, Amazon Web Services Data storage and management, Business Partnering implementation, streamlining of architecture landscape
- Legal Compliance - Ensured company's compliance with relevant laws and regulations, including contract negotiation and management with particular focus on GDPR legislation
- Enhancement of Financial, IT & Legal team profile by optimizing skills, improving commitment, business awareness and overall motivation
- Currently leading ~100 FTE's (40 Finance, 50 IT and 10 Legal)
- Successful implementation of SOX environment in 12 months from scratch (NPI)
- PE Backed NASDAQ Listed Exome and Genome Diagnostics and Pharma services provider expert in Rare Diseases
GENERAL MANAGER SOUTHERN EUROPE
ORPHAZYME A/S
Madrid
02.2021 - 09.2021
- Company Overview: Pre-Clinical Rare Diseases Pharma Biotech with Arimoclomol as main asset aiming to treat Niemann Pick Type C, ALS, IBM and Gaucher
- Implementation of all pre-launch commercial activities including Price and Reimbursement dossiers for Spain and Italy
- Launched Early Access Program for the full cluster (Spain, Italy, Portugal and Greece), engagement with key stakeholders, Key opinion leaders, payers, etc
- Orphazyme was massively affected by the non-approval by FDA of his only product Arimoclomol in Jun 2021
- That forced the reduction of 70% of the headcount worldwide prioritizing EMA and FDA approval needed resources
- Pre-Clinical Rare Diseases Pharma Biotech with Arimoclomol as main asset aiming to treat Niemann Pick Type C, ALS, IBM and Gaucher
CFO EMEA
MUNDIPHARMA
Madrid - Cambridge
01.2020 - 01.2021
- Company Overview: Pharmaceutical Company with special focus on Pain and Biosimilar businesses
- Revenues +$2b
- Oversight Finance function on a +$1B operation with a team of more than +70 FTE's located in Europe and MEA
- Drive a deep financial transformation impacting every aspect of the function with clear focus on building the Business Partnering activities and start acting as a reliable source of information and insights for the Business decision
- Setup of all Financial processes and structure from an atomized management to a consolidated approach
- Implementation of P/L, Balance Sheet, Cash Flow views that did not exist in the past
- Implementation and Development of Business Partnering function with clear focus on change management and engagement with Commercial function that never had interaction with Finance
- Material reduction of Working Capital by optimization of each component – Inventories, Accounts Receivable and Accounts Payable
- Pharmaceutical Company with special focus on Pain and Biosimilar businesses
- Revenues +$2b
SENIOR EXTERNAL CORPORATE CONSULTANT
STADA AG
Frankfurt
08.2019 - 12.2019
- Company Overview: Pharmaceutical Multinational focused mostly on Pain and Biosimilar Businesses +€2B
- Working closely with the Group CFO and CEO manage and implement a full program focused on G&A savings with a budget of +€200m aiming to find the most effective efficiencies and investment prioritization
- Design and implement a new CAPEX monitoring and optimization process
- Pharmaceutical Multinational focused mostly on Pain and Biosimilar Businesses +€2B
GENERAL MANAGER ANDEAN REGION
SHIRE PHARMACEUTICALS
Bogotá
04.2018 - 05.2019
- Company Overview: Pharma Biotech +€30B- with focus mainly on Rare Diseases, Hematology, Immunology, Neurology and Gastroenterology
- Lead operations in Colombia, Ecuador, Peru and Venezuela reporting to the President of LATAM
- Revenues of $130m with a team of 90 FTE's
- More than 20 products commercialized in Hematology, Rare Diseases, Immunology, Gastroenterology and Internal Medicine
- Exceed budget in 2018 +4% and +13% growth vs 2017
- Turnaround in the Commercial Strategy, Patient Support Program, Donations strategy, Value Demonstration & Access on Customer Price and Conditions setting up the fundamentals for the successful evolution of the business obtaining a +6% margin improvement and +4% revenue increase
- Setup Ecuador and Peru operations moving away from distributor model
- Successful launch of three products (HyQvia, Cinryze and Revestive) exceeding initial targets
- Pharma Biotech +€30B- with focus mainly on Rare Diseases, Haematology, Immunology, Neurology and Gastroenterology
CFO LATAM
SHIRE PHARMACEUTICALS
Sao Paulo
07.2014 - 04.2018
- Company Overview: Pharma Biotech +€30B- with focus mainly on Rare Diseases, Haematology, Immunology, Neurology and Gastroenterology
- Build and lead a +60 team members, both Controlling and FP&A/FBP in 14 different countries being the Business Partner for the President of LATAM moving from revenues $250m in 2014 to $750m in 2018
- Successfully manage merge and integration of Shire-Baxalta with +10 different systems, Share Service Centre setup in Exton (US)
- Creation of Business Partnering team in all the region aiming to be the best senior advisor to the business customers
- Obtained 90% successful Internal Audit reports
- Pharma Biotech +€30B- with focus mainly on Rare Diseases, Haematology, Immunology, Neurology and Gastroenterology
CFO IBERIA
SHIRE PHARMACEUTICALS
Madrid
03.2011 - 06.2014
- Company Overview: Pharma Biotech +€30B- with focus mainly on Rare Diseases, Haematology, Immunology, Neurology and Gastroenterology
- Lead the finance and business services team in ensuring the integrity of all financial statements for the Spanish and Portuguese legal entities with 8 team members (6 Spain, 2 in Portugal)
- Act as a Business Partner for the two existing GM's continue contribution on business decisions and the strategic planning of the affiliate
- Implementation of correct Financial and Accounting processes addressing all audit findings
- Setup of FP&A and Business Partnering functions serving two different GM's (Rare Diseases and Specialty Pharma)
- Improvement of Outstanding Accounts Receivable mostly on public accounts with some customers +700 days DSO's
- Successful launch of three products (HyQvia, Cinryze and Revestive) surpassing initial targets
- Pharma Biotech +€30B- with focus mainly on Rare Diseases, Haematology, Immunology, Neurology and Gastroenterology
Director of Volvo Car Financial Services
VOLVO CAR ESPAÑA
Madrid
02.2010 - 02.2011
Iberian Business Controller
VOLVO CAR ESPAÑA
Madrid
07.2006 - 01.2010
- Reviewed contracts financially impacting company and counseled executive leaders on impact contracts would have on company operations.
- Optimized resource allocation through effective capital planning and prioritization.
Controller Project Manager
SAUR INTERNATIONAL
Madrid
10.2004 - 06.2006
Financial Controller
SHELL ESPAÑA
Madrid
07.2003 - 09.2004
Treasurer
SHELL FINANCIAL OPPS SCOTLAND
07.2001 - 07.2003
GL Sr Accountant
SHELL FINANCIAL OPPS SCOTLAND
AR Accountant
SHELL FINANCIAL OPPS SCOTLAND
Education
BACHELOR HONS - ECONOMICS
Abertay University
Dundee, UK 08.2000 - 07.2001
Skills
- Business Partnering
- Investor Relationships
- PE Backed NASDAQ and SEC compliance
- SOX implementation
- Processes Optimization
- Financing raising
- Banking relationships
- Analysts relationships
- Auditors relationships
- Strong Leadership
- Splendid Communication Skills
- Turnaround Projects
- Financial Processes Setup and Enhancement
- M&A
- Negotiations skills
- SOX and ERP implementation
- Process Improvements
- FBP Excellence
- Change Management
- Critical Thinking
- Investment Optimization
- Commercial Excellence
- Financial reporting
- Financial statement review
Pastprofessionalexperience
- Director of Volvo Car Financial Services, Volvo Car España, Madrid, Spain, 02/01/10, 02/01/11
- Iberian Business Controller, Volvo Car España, Madrid, Spain, 07/01/06, 01/01/10
- Controller Project Manager, Saur International, Madrid, Spain, 10/01/04, 06/01/06
- Financial Controller, Shell España, Madrid, Spain, 07/01/03, 09/01/04
- Treasurer, Shell Financial Ops Scotland, Glasgow, UK, 07/01/01, 07/01/03
- GL Sr Accountant, Shell Financial Ops Scotland, Glasgow, UK
- AR Accountant, Shell Financial Ops Scotland, Glasgow, UK
Timeline
CHIEF FINANCIAL OFFICER, IT AND LEGAL
CENTOGENE NV
02.2022 - 12.2024
GENERAL MANAGER SOUTHERN EUROPE
ORPHAZYME A/S
02.2021 - 09.2021
CFO EMEA
MUNDIPHARMA
01.2020 - 01.2021
SENIOR EXTERNAL CORPORATE CONSULTANT
STADA AG
08.2019 - 12.2019
GENERAL MANAGER ANDEAN REGION
SHIRE PHARMACEUTICALS
04.2018 - 05.2019
CFO LATAM
SHIRE PHARMACEUTICALS
07.2014 - 04.2018
CFO IBERIA
SHIRE PHARMACEUTICALS
03.2011 - 06.2014
Director of Volvo Car Financial Services
VOLVO CAR ESPAÑA
02.2010 - 02.2011
Iberian Business Controller
VOLVO CAR ESPAÑA
07.2006 - 01.2010
Controller Project Manager
SAUR INTERNATIONAL
10.2004 - 06.2006
Financial Controller
SHELL ESPAÑA
07.2003 - 09.2004
Treasurer
SHELL FINANCIAL OPPS SCOTLAND
07.2001 - 07.2003
BACHELOR HONS - ECONOMICS
Abertay University
08.2000 - 07.2001
GL Sr Accountant
SHELL FINANCIAL OPPS SCOTLAND
AR Accountant
SHELL FINANCIAL OPPS SCOTLAND
Similar Profiles
Chukwunonso Chuka NnabudeChukwunonso Chuka Nnabude
Biological Technical Assistant at CENTOGENE GmbHBiological Technical Assistant at CENTOGENE GmbH
MD FARUQUE ANSARIMD FARUQUE ANSARI
Business Development Manager at CENTOGENEBusiness Development Manager at CENTOGENE
Pradeep AsuriPradeep Asuri
AWS DevOps Engineer at Centogene GmbHAWS DevOps Engineer at Centogene GmbH